The company - which produces nucleic acid biopharmaceuticals including gene therapies, DNA vaccines, and RNA medicines - says the new facility will help it meet increasing demand.
“VGXI’s clients and collaborators are developing the next generation of gene therapies and vaccines,” said CEO Young Park. “This new VGXI headquarters is purpose-built to leverage the company’s existing expertise in DNA and RNA manufacturing and greatly expand our capacity to support growing industry demands.”
VGXI has operated as a CDMO since 2003 out of The Woodlands, Texas: supporting the development of new cancer therapies, gene and cell therapies, and DNA vaccines for critical emerging diseases including Ebola, MERS, Zika, and COVID-19.
The new VGXI headquarters features 4 distinct manufacturing trains with state-of-the-art production equipment, flexible fermentation capacity, and expanded GMP fill/finish capabilities.
With expanded capabilities offered by the 120,000 square-foot Conroe facility, the company is now booking 2023 GMP manufacturing slots at fermentation scales from 10L to 1500L across multiple independent manufacturing trains.
Dedicated areas are also available for personalized immunotherapy indications and GMP mRNA production.
VGXI, a company from South Korea’s GeneOne, held an official grand opening of the new headquarters and manufacturing facility at Deison Technology Park was held last week. The event was attended by US Congressman Kevin Brady and the Consul General of the Republic of Korea in Houston, Ahn Myung Soo.
